NIR spectroscopy applications in the development of a compacted multiparticulate system for modified release.
The purpose of this study was to utilize near-infrared spectroscopy and chemical imaging to characterize extrusion-spheronized drug beads, lipid-based placebo beads, and modified release tablets prepared from blends of these beads. The tablet drug load (10.5-19.5 mg) of theophylline (2.25 mg increments) and cimetidine (3 mg increments) could easily be differentiated using univariate analyses. To evaluate other tablet attributes (i.e., compression force, crushing force, content uniformity), multivariate analyses were used. Partial least squares (PLS) models were used for prediction and principal component analysis (PCA) was used for classification. The PLS prediction models (R (2) >0.98) for content uniformity of uncoated compacted theophylline and cimetidine beads produced the most robust models. Content uniformity data for tablets with drug content ranging between 10.5 and 19.5 mg showed standard error of calibration (SEC), standard error of cross-validation, and standard error of prediction (SEP) values as 0.31, 0.43, and 0.37 mg, and 0.47, 0.59, and 0.49 mg, for theophylline and cimetidine, respectively, with SEP/SEC ratios less than 1.3. PCA could detect blend segregation during tableting for preparations using different ratios of uncoated cimetidine beads to placebo beads (20:80, 50:50, and 80:20). Using NIR chemical imaging, the 80:20 formulations showed the most pronounced blend segregation during the tableting process. Furthermore, imaging was capable of quantitating the cimetidine bead content among the different blend ratios. Segregation testing (ASTM D6940-04 method) indicated that blends of coated cimetidine beads and placebo beads (50:50 ratio) also tended to segregate.
School of Pharmacy, University of Maryland, 20 N. Pine Street, Baltimore, Maryland 21201, USA.
Stuart L
SL
Cantor
Stephen W
SW
Hoag
Christopher D
CD
Ellison
Mansoor A
MA
Khan
Robbe C
RC
Lyon
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry; D002927:Cimetidine / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D003692:Delayed-Action Preparations; D004304:Dosage Forms; D016503:Drug Delivery Systems; D005079:Excipients / Q000737:chemistry; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008689:Methacrylates / Q000737:chemistry; D015233:Models, Statistical; D010919:Placebos; D011108:Polymers / Q000737:chemistry; D019265:Spectroscopy, Near-Infrared / Q000379:methods*; D013607:Tablets; D013806:Theophylline / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology
D000897:Anti-Ulcer Agents; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D004304:Dosage Forms; C477853:Eudragit NE 30-D; D005079:Excipients; D008055:Lipids; D008689:Methacrylates; D010919:Placebos; D011108:Polymers; D013607:Tablets; C013517:ethyl cellulose; D002927:Cimetidine; D002482:Cellulose; D013806:Theophylline
Drug Dev Ind Pharm. 1999 Dec;25(12):1267-70
10612022
J Pharm Biomed Anal. 2007 Jul 27;44(3):683-700
17482417
J Pharm Biomed Anal. 1998 Jun;17(2):219-25
9638573
Analyst. 1999 Jan;124(1):33-6
10563043
AAPS PharmSciTech. 2005 Sep 30;6(2):E174-83
16353975
Analyst. 2001 Dec;126(12):2207-11
11814203
Pharm Dev Technol. 2001;6(1):19-29
11247272
AAPS PharmSciTech. 2005 Sep 20;6(1):E91-9
16353969
J Pharm Biomed Anal. 1999 Mar;19(3-4):351-62
10704101
Adv Drug Deliv Rev. 2004 Feb 23;56(3):349-69
14962586
Pharm Dev Technol. 2003;8(4):357-66
14601960
Analyst. 1999 Feb;124(2):163-7
10563053
J Pharm Sci. 2005 Jul;94(7):1589-97
15924348
J Pharm Sci. 1990 Jul;79(7):622-7
2398471
Drug Dev Ind Pharm. 2009 Jun;35(6):683-93
19412830
J Pharm Sci. 2006 Oct;95(10):2137-44
16883562
Pharm Res. 1997 Jan;14(1):108-11
9034230
J Pharm Biomed Anal. 2000 Jun;22(5):829-48
10815725
Adv Drug Deliv Rev. 2005 Jun 15;57(8):1109-43
15899537
J Pharm Sci. 2006 Jul;95(7):1425-33
16721793
J Pharm Biomed Anal. 1996 Aug;14(11):1495-503
8877855
J Pharm Sci. 2009 Mar;98(3):1095-109
18623193
Anal Chem. 2003 Feb 15;75(4):754-60
12622363
AAPS PharmSciTech. 2005 Oct 06;6(2):E273-83
16353987
Analyst. 1998 Nov;123(11):2297-302
10396806
J Pharm Sci. 2008 Oct;97(10):4485-97
18271036
Drug Dev Ind Pharm. 2009 Mar;35(3):337-51
18798034
J Pharm Sci. 2007 Dec;96(12):3390-401
17630646
J Pharm Biomed Anal. 1996 Sep;14(12):1681-9
8887715
Int J Pharm. 2005 Dec 8;306(1-2):56-70
16266793
AAPS PharmSciTech. 2002;3(3):E17
12916932
Drug Dev Ind Pharm. 2001 Aug;27(7):623-31
11694009
J Pharm Sci. 2003 Jul;92(7):1526-30
12820157
Eur J Pharm Biopharm. 2000 Sep;50(2):271-6
10962238
Drug Dev Ind Pharm. 2009 May;35(5):568-82
18979306